The Efficacy and Tolerability of Canagliflozin in Healthy Individual
Conditions: Healthy Aging Interventions: Drug: Invokana Pill Sponsors: AgelessRx Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
Conditions: Polycystic Ovary Syndrome; Non-Alcoholic Fatty Liver Disease Interventions: Drug: Canagliflozin 100mg Tab; Drug: Metformin Hydrochloride Sponsors: Ping Li,MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Canagliflozin in Advanced Renal Disease With MRI Endpoints
Conditions: ESRD, CKD Stage 4, CKD Stage 5 Interventions: Drug: Canagliflozin 300Mg Tab; Drug: Placebo Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Heart and Stroke Foundation of Canada Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: Canagliflozin; Drug: DPP4 inhibitor; Drug: Liraglutide; Drug: Saxagliptin; Drug: 2nd generation Sulfonylurea Sponsors: AstraZeneca Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Low-carbohydrate diet in the treatment of type 2 diabetes mellitus (LoCaT): study protocol for a multicenter, randomized controlled trial
In this study, we aim to compare the effects of LCD and canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with T2DM.MethodsThis is a multicenter, randomized controlled trial. We will recruit 120 patients with poor-controlled T2DM. Participants will be randomly divided into canagliflozin and LCD groups in a 1:1 ratio. The primary outcome is the change in hemoglobin A1C levels after the 3-month intervention. The secondary outcomes are the time in range and cost of antihyperglycemic agents. Exploratory outcomes include physical examination, body composition, glucose variability, appetite, glycolipid metab...
Source: Trials - June 19, 2023 Category: Research Source Type: clinical trials
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
Condition: Pancreatic Cancer Interventions: Drug: Canagliflozin and Gemcitabine; Drug: Gemcitabine Sponsors: Zhang Xiaofeng,MD; College of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
